ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP (CAS: 72242-03-6) and 4-MeO-PCP (CAS: 2201-35-6)-a multi-in silico approach for comprehensive prediction of absorption, distribution, metabolism and excretion relevant to clinical and forensic toxicology.
Archives of toxicology – January 28, 2026
Source: PubMed
Summary
New psychoactive substances like 3-MeO-PCP and 4-MeO-PCP, relatives of Phencyclidine, are predicted to readily cross the blood-brain barrier. An in silico analysis revealed their concerning toxicokinetic profiles, showing high gastrointestinal absorption and extensive tissue distribution. Both bind extensively to plasma proteins, around 70-80%. This ADME characterization supports targeted bioanalysis and informs clinical management, highlighting potential drug-drug interactions. This robust computational approach offers a vital tool for understanding these emerging compounds when human data is scarce.
Abstract
A multi-platform in silico workflow was applied to characterize the ADME profile of the methoxy-substituted phencyclidines 3-MeO-PCP and 4-MeO-PCP for clinical toxicological and forensic use. Predictions from ACD/Percepta, SwissADME, pkCSM, ADMETlab 3.0, DruMAP 2.0 and XenoSite were triangulated under OECD (Q)SAR principles with explicit applicability-domain checks. Both analogues were predicted to exhibit high passive permeability, high gastrointestinal absorption, and blood-brain barrier access. Distribution outputs consistently indicated extensive tissue partitioning, high plasma protein binding (~ 70-80%), and large apparent volumes of distribution. Metabolic liability was assigned primarily to CYP3A4, CYP2D6 and CYP2C19, with early O-demethylation to phenolic metabolites followed by rapid glucuronidation; modelled CYP values support clinically relevant drug-drug interaction and genotype effects. XenoSite suggested a higher theoretical bioactivation propensity for 4-MeO-PCP via arene-oxide/quinone-methide manifolds. Excretion modules predicted renal transporter involvement, while total clearance and half-life estimates showed method-dependent dispersion. The consolidated profile supports targeted bioanalysis (phenolic O-glucuronides; adduct screening in severe cases), informs matrix selection and exposure back-extrapolation, and prioritizes validation studies (recombinant CYP phenotyping, transporter assays, protein/brain binding). The workflow generalizes to related dissociatives and provides a transparent, regulator-aligned template for rapid ADME risk triage when in vivo data are limited.